Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2011 (2011), Article ID 707126, 5 pages
http://dx.doi.org/10.1155/2011/707126
Clinical Study

The Serum Level of Fibroblast Growth Factor-23 and Calcium-Phosphate Homeostasis in Obese Perimenopausal Women

1Department of Internal Medicine and Metabolic Diseases, Medical University of Silesia, ul. Ziołowa 45/47, 40-635 Katowice, Poland
2Department of Pathophysiology, Medical University of Silesia, ul. Medyków 18, 40-752 Katowice, Poland
3Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, ul. Francuska 20-24, 40-027 Katowice, Poland

Received 25 July 2011; Revised 18 October 2011; Accepted 18 October 2011

Academic Editor: Vin Tangpricha

Copyright © 2011 M. Holecki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Plasma FGF-23 concentrations and its relationship with calcium-phosphate homeostasis were evaluated in 48 perimenopausal obese women and in 29 nonobese controls. Serum parathyroid hormone, 25-hydroxyvitamin D3, CTX1, osteocalcin, total calcium, phosphorus, creatinine, and plasma intact FGF-23 concentrations were assessed. DXA of lumbar spine and femoral neck was performed to determine bone mineral density (BMD). Plasma iFGF-23 concentration was significantly higher in obese patients (by 42%) and correlated with age and BMD of proximal femur ( ; , resp.) but not with markers of bone turnover. However, serum phosphorus level in obese subjects was significantly lower. iFGF-23 concentration correlated significantly with body mass index ( ) and fat content ( ) in all study subjects. Moreover, a significant correlation between iFGF-23 and iPTH ( ) was found. No correlation between serum phosphorus or eGFR and plasma iFGF-23 and between eGFR and serum phosphorus was found. Elevated serum iFGF-23 concentration may partially explain lower phosphorus levels in the obese and seems not to reflect bone turnover.